Education
About Us
Working with TipRanks
Follow Us
Virax Biolabs Group Ltd. Class A (VRAX)
NASDAQ:VRAX
VRAX Stock Chart & Stats
$0.36
-$0.38(-13.72%)
At close: 4:00 PM EST
$0.36
-$0.38(-13.72%)
Day’s Range― - ―
52-Week Range$0.35 - $3.20
Previous CloseN/A
Volume267.06K
Average Volume (3M)315.79K
Market Cap
$1.56M
Enterprise ValueN/A
Total Cash (Recent Filing)$3.35M
Total Debt (Recent Filing)$537.99K
Price to Earnings (P/E)―
Beta2.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.37
Shares Outstanding4,341,956
10 Day Avg. Volume262,895
30 Day Avg. Volume315,785
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.62
Price to Sales (P/S)557.69
P/FCF Ratio-0.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical StudiesThe company is initiating a U.S.-based clinical validation study to support the development of its ViraxImmune platform.
Market ExpansionManagement expects to expand ImmuneSelect distribution channels into the U.S markets.
Bears Say
Regulatory ChallengesThe company is still in the development stage, which may present challenges in obtaining necessary regulatory approvals for its diagnostics.
Virax Biolabs Group Ltd. Class A News
VRAX FAQ
What was Virax Biolabs Group Ltd. Class A’s price range in the past 12 months?
Virax Biolabs Group Ltd. Class A lowest stock price was $0.35 and its highest was $3.20 in the past 12 months.
What is Virax Biolabs Group Ltd. Class A’s market cap?
Virax Biolabs Group Ltd. Class A’s market cap is $1.56M.
When is Virax Biolabs Group Ltd. Class A’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Virax Biolabs Group Ltd. Class A’s earnings last quarter?
Currently, no data Available
Is Virax Biolabs Group Ltd. Class A overvalued?
According to Wall Street analysts Virax Biolabs Group Ltd. Class A’s price is currently Overvalued.
Does Virax Biolabs Group Ltd. Class A pay dividends?
Virax Biolabs Group Ltd. Class A does not currently pay dividends.
What is Virax Biolabs Group Ltd. Class A’s EPS estimate?
Virax Biolabs Group Ltd. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Virax Biolabs Group Ltd. Class A have?
Virax Biolabs Group Ltd. Class A has 4,341,956 shares outstanding.
What happened to Virax Biolabs Group Ltd. Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Virax Biolabs Group Ltd. Class A?
Currently, no hedge funds are holding shares in VRAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
Technical Analysis
Biodexa Pharmaceuticals
―
Scinai Immunotherapeutics
―
―
Aditxt
―
Dermata Therapeutics
―
Ownership Overview
―
Insiders
0.49% Other Institutional Investors
99.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---